From President Beverley Yamamoto, HAE Japan

The non-profit organization Discovery Consortium has been established in Japan to try and lift the diagnosis rate for HAE up to the kind of levels seen in North America and Europe. At the moment we estimate that only 20 % of all Japanese patients have been diagnosed.

The majority of the funding for the project is coming from the pharmaceutical companies, with equal funding from Takeda, CSL, and Torii who represent BioCryst in Japan. I am on the Board of Directors along with the leading doctors in the field. 

>> Read more about HAE Japan on the country page for Japan